Literature DB >> 11820619

Significance of cell adhesion molecules, CD56/NCAM in particular, in human tumor growth and spreading.

J Zeromski1, E Nyczak, W Dyszkiewicz.   

Abstract

Cell adhesion molecules (CAM) represent a large group of cell surface protein moieties with distinctive biological functions. In physiological terms they ascertain cell to cell contact such as cell cohesion of epithelia, condition cell migration and transmigration via biological membranes such as blood vessel walls, provide means for homing cells in a new microenvironment etc. These features of CAM are exploited by tumor cells to grow and spread in a tumor bearing host. CD56/N-CAM antigen is 140 kD isoform of neural cell adhesion molecule. N-CAM belongs to the large Ig superfamily of CAMs. CD56 can be traced at various sites, including nervous tissue, neuro-muscular junctions, neuroendocrine and endocrine organs. It is well known as a differentiation antigen of natural killer (NK) cells. Its role and function are far from clear, but its adhesion properties are evident in cell-cell (homophilic) interactions. CD56 has been, however, demonstrated the cells various human malignancies. Tumors of the nervous system such as neuroblastoma, are well known to express this marker. Malignant lymphomas of T-NK cell origin bear CD56, as well as multiple myeloma, melanoma and some cancers of epithelial origin. These data suggest that CD56/N-CAM antigen is, in some unknown manner involved in tumor biology.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11820619

Source DB:  PubMed          Journal:  Folia Histochem Cytobiol        ISSN: 0239-8508            Impact factor:   1.698


  11 in total

1.  Structural characterization of the maytansinoid-monoclonal antibody immunoconjugate, huN901-DM1, by mass spectrometry.

Authors:  Lintao Wang; Godfrey Amphlett; Walter A Blättler; John M Lambert; Wei Zhang
Journal:  Protein Sci       Date:  2005-08-04       Impact factor: 6.725

2.  CD56/NCAM-positive Langerhans cell sarcoma: a clinicopathologic study of 4 cases.

Authors:  Takakazu Kawase; Minoru Hamazaki; Michinori Ogura; Yoshiaki Kawase; Toshihiko Murayama; Yoshio Mori; Hirokazu Nagai; Masatoshi Tateno; Takashi Oyama; Yoshikazu Kamiya; Hirofumi Taji; Yoshitoyo Kagami; Tomoki Naoe; Toshitada Takahashi; Yasuo Morishima; Shigeo Nakamura
Journal:  Int J Hematol       Date:  2005-05       Impact factor: 2.490

Review 3.  The biological characterization of neuroendocrine tumors: the role of neuroendocrine markers.

Authors:  P Ferolla; A Faggiano; G Mansueto; N Avenia; M G Cantelmi; P Giovenali; M L Del Basso De Caro; F Milone; G Scarpelli; S Masone; F Santeusanio; G Lombardi; G Angeletti; A Colao
Journal:  J Endocrinol Invest       Date:  2008-03       Impact factor: 4.256

4.  Phase I study of IMGN901, a CD56-targeting antibody-drug conjugate, in patients with CD56-positive solid tumors.

Authors:  Manisha H Shah; Paul Lorigan; Mary E R O'Brien; Frank V Fossella; Kathleen N Moore; Shailender Bhatia; Maurice Kirby; Penella J Woll
Journal:  Invest New Drugs       Date:  2016-03-09       Impact factor: 3.850

5.  Contextualizing the Genes Altered in Bladder Neoplasms in Pediatric andTeen Patients Allows Identifying Two Main Classes of Biological ProcessesInvolved and New Potential Therapeutic Targets.

Authors:  A Porrello; R B Piergentili
Journal:  Curr Genomics       Date:  2016-02       Impact factor: 2.236

6.  CD56 Expression Is Associated with Biological Behavior of Pancreatic Neuroendocrine Neoplasms.

Authors:  Xin Chen; Chuangen Guo; Wenjing Cui; Ke Sun; Zhongqiu Wang; Xiao Chen
Journal:  Cancer Manag Res       Date:  2020-06-17       Impact factor: 3.989

Review 7.  Strategies to Improve Chimeric Antigen Receptor Therapies for Neuroblastoma.

Authors:  Piamsiri Sawaisorn; Korakot Atjanasuppat; Usanarat Anurathapan; Somchai Chutipongtanate; Suradej Hongeng
Journal:  Vaccines (Basel)       Date:  2020-12-11

8.  CEA Level, Radical Surgery, CD56 and CgA Expression Are Prognostic Factors for Patients With Locoregional Gastrin-Independent GNET.

Authors:  Yuan Li; Xinyu Bi; Jianjun Zhao; Zhen Huang; Jianguo Zhou; Zhiyu Li; Yefan Zhang; Muxing Li; Xiao Chen; Xuhui Hu; Yihebali Chi; Dongbing Zhao; Hong Zhao; Jianqiang Cai
Journal:  Medicine (Baltimore)       Date:  2016-05       Impact factor: 1.889

Review 9.  Chromosomal instability and acquired drug resistance in multiple myeloma.

Authors:  Wang Wang; Yi Zhang; Ruini Chen; Zhidan Tian; Yongpin Zhai; Siegfried Janz; Chunyan Gu; Ye Yang
Journal:  Oncotarget       Date:  2017-09-11

Review 10.  CAR T Cell Therapy for Neuroblastoma.

Authors:  Rebecca M Richards; Elena Sotillo; Robbie G Majzner
Journal:  Front Immunol       Date:  2018-10-16       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.